Clinical Trial Update: Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 lentiviral gene therapy trial for ADA deficiency/SCID completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosine Deaminase Deficiency
• Combined Immunodeficiencies

Drugs mentioned

• Lentiviral gene therapy

Snippet

Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Conditions: Adenosine Deaminase Deficiency, Severe Combined Immunodeficiencies (SCID) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-16